Table 1.
Summary of UCNPs combined with immunotherapy.
| Nanocarrier | UCNPs | Immunotherapy agents | References |
|---|---|---|---|
| UCNP-PEG-PEI | NaY/GdF4 (Y:Gd:Yb:Er = 58%:20%:20%:2%) | OVA | Xiang et al., 2015 |
| Monodispersed macroporous mesoporous silica-coated upconversion nanoparticles (UCMSs) | β-NaYF4:20%Yb,2%Er | OVA/tumor cell fragment (TF) | Ding et al., 2018 |
| SA-PEG-TK-PLGA (SPTP) | β-NaYF4:20%Yb,2%Er | DOX and RB | Jin et al., 2020 |
| UCNPs | NaYF4:20%Yb,2%Er | R837 and CTLA-4 immune checkpoint inhibitors | Xu et al., 2017a |
| UCNP@SiO2 | NaYF4:Yb,Er | Anti-CTLA-4 | Lin et al., 2020 |
| UCNPs | NaYF4:48%Yb/2%Er@NaYF4:30%Nd Core/Shell Nanoparticles | Anti-CTLA-4 | Wang et al., 2019a |
| PDA@UCNP-PEG | NaGdF4:Yb/Er | α-PD-1 | Yan et al., 2019 |
| AIE luminogen (AIEgen)–coupled UCNPs (AUNPs) | NaYF4:Yb/Tm@NaYF4 | α-PD-1 | Mao et al., 2020 |
| UCNPs@porphyrin MOFs (UCSs) | NaGdF4:Yb,Er@NaGdF4 | α-PD-L1 | Shao et al., 2020 |
| UCNPs | NaGdF4:Yb,Er@NaYF4@NaYF4:Yb,Tm@NaYbF4:Nd@NaYF4 | α-PD-L1 | Di et al., 2020 |
| UCNPs | NaGdF4:70%Yb,1%Tm@NaGdF4 core-shell UCNPs | CpG ODNs | Chu et al., 2019 |
| UCNPs@mesoporous silica | NaYF4:Er/Yb | CCL21 | Lee et al., 2013 |
| UCNs-MnO2 | NaYF4:Yb/Tm/Nd (30/0.5/1%)@NaYF4:Nd (20%) | HA | Ai et al., 2018 |
| Bi doped mesoporous upconversion nanophosphor (UCNP) | Na0.2Bi0.8O0.35F1.91:20%Yb,2%Er | DOX and X-ray | Qin et al., 2020 |